Rachel King compensation by year
CRESCENT BIOPHARMA Summary Compensation Table · all 5 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Salary | $502,500 | $543,000 | $559,300 | $576,079 | $511,146 |
| Bonus | $0 | $0 | $0 | $279,650 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $366,713 |
| Option awards | $747,250 | $2,350,250 | $1,844,400 | $1,190,090 | $520,955 |
| Non-equity incentive | $301,500 | $286,704 | $276,854 | $332,686 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $4,050 | $5,199 | $8,519 | $8,645 | $22,034 |
| Total | $1,555,300 | $3,185,153 | $2,689,073 | $2,387,150 | $1,420,848 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 11, 2022, accession 0001558370-22-005265, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-22-005265. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 96,250 | $138,600 | — |
| Option | 192,500 | — | $3.81 |
| Option | 181,770 | — | $4.72 |
| Option | 71,770 | — | $10.59 |
| Option | 3,645 | — | $20.03 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2021 proxy (filed April 11, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-05-01 | Grant or award derivative | — | 40,000 | $0.00 | 40,000 |
| 2024-03-29 | Grant or award | — | 3,334 | $3.00 | 515,194 |
| 2023-12-29 | Grant or award | — | 4,238 | $2.36 | 511,860 |
| 2023-09-30 | Grant or award | — | 6,667 | $1.50 | 507,622 |
| 2023-05-19 | Grant or award derivative | — | 35,000 | $0.00 | 35,000 |
| 2022-08-02 | W | — | 7,500 | $0.00 | 7,500 |
| 2022-02-15 | W | — | 11,641 | $0.00 | 500,955 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CRESCENT BIOPHARMA’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Harout Semerjian | President and Chief Executive Officer | $2,876,118 |
| Rachel King · this page | Former President and Chief Executive Officer | $1,420,848 |
| Brian Hahn | Senior Vice President and Chief Financial Officer | $1,122,561 |
| John Magnani | Senior Vice President of Research and Chief Scientific Officer | $1,121,337 |
Board service
CRESCENT BIOPHARMA board · FY2021–FY2023| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2023 | $40,000 | — | $56,000 | — | $96,000 |
| FY2022 | $40,000 | — | $9,240 | $186,433 | $235,673 |
| FY2021 | $0 | $0 | $0 | — | — |
Each year as the company reported it in CRESCENT BIOPHARMA's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: CRESCENT BIOPHARMA pays directors a $40,000 cash retainer. As stated in CRESCENT BIOPHARMA's FY2023 proxy.
The full CRESCENT BIOPHARMA compensation record
free company briefThis page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CRESCENT BIOPHARMA proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.